AbbVie Inc.
ABBV
Below: live stock price for AbbVie Inc. (ABBV), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
AbbVie Inc. (ABBV) is a Healthcare company based in United States. Operating in Drug Manufacturers - General, it employs about 57,000 people. Over the past year ABBV traded between 184.63 and 261.64 USD. Trailing P/E sits near 124.75 on a market cap of about 449.63B USD. It currently yields 2.72% in dividends.
- Prev close
- $254.39
- Volume (24h)
- $1.33B
- Market cap
- $449.63B
- Currency
- USD
Score
42/ 100 · Weak
- Value50
- Quality66
- Momentum58
- Growth23
- Risk73
- Dividend17
- Liquidity9
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 258.9941 +1.77%
- +20 bars
- 265.3399 +4.26%
- +60 bars
- 267.8363 +5.24%
- +120 bars
- 267.9283 +5.28%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: ±0.0275 USD.
Interpretation
Composite signals look weak. Strength: risk profile with weakness: balance-sheet liquidity. Price sits near the upper third of the recent range, trend is sloping upward.
Descriptive observation — not investment advice.
Score breakdown
Raw values behind each pillar so you can see what the composite is reading.
- Value50/100
Value looks mixed — driven by P/E (124.75).
P/E:124.75PEG:0.42 - Quality66/100
Quality looks solid — driven by Gross margin (72.03%).
ROA:10.03%Profit margin:5.79%Gross margin:72.03% - Momentum58/100
Momentum looks mixed — driven by 52w change (37.67%).
52w change:37.67% - Growth23/100
Growth looks fragile — driven by Earnings growth (-46.20%).
Revenue growth:12.40%Earnings growth:-46.20% - Risk73/100
Risk looks solid — driven by Beta (0.28).
Beta:0.28Short interest:1.38% - Dividend17/100
Dividend looks fragile — driven by Payout ratio (325.98%).
Dividend yield:2.72%Payout ratio:325.98% - Liquidity9/100
Liquidity looks fragile — driven by Current ratio (0.8).
Current ratio:0.8Quick ratio:0.52
Derived from public market data — informational, not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
- ResistanceFib +161.8% extension376.3401 USD+47.88% from current
- ResistanceFib +100% extension332.53 USD+30.67% from current
- ResistanceFib +61.8% extension305.45 USD+20.02% from current
- ResistanceFib +27.2% extension280.9221 USD+10.39% from current
- Current254.49 USD
- SupportFib 23.6% retracement244.91 USD-3.76% from current
- SupportFib 38.2% retracement234.56 USD-7.83% from current
- SupportFib 50% midpoint226.195 USD-11.12% from current
- SupportFib 61.8% retracement217.83 USD-14.41% from current
- SupportFib 78.6% retracement205.9205 USD-19.09% from current
- SupportFib −27.2% extension171.4679 USD-32.62% from current
- SupportFib −61.8% extension146.94 USD-42.26% from current
- SupportFib −100% extension119.86 USD-52.90% from current
Financials
- 52w high
- $261.64
- 52w low
- $184.63
- 52w change
- 37.67%
- Day high
- $260.84
- Day low
- $254.29
- P/E (TTM)
- 124.75
- Forward P/E
- 15.63
- PEG
- 0.42
- Beta (5Y)
- 0.28
- Enterprise value
- 513.2B
- EV / Revenue
- 8.17
- EV / EBITDA
- 17.16
- EPS (TTM)
- $2.04
- Forward EPS
- $16.28
- Dividend yield
- 2.72%
- Dividend rate
- $6.92
- Payout ratio
- 325.98%
- Revenue (TTM)
- 62.82B
- EBITDA
- 29.92B
- Free cash flow
- 20.81B
- Total cash
- 9.39B
- Total debt
- 72.91B
- Current ratio
- 0.8
- Quick ratio
- 0.52
- Profit margin
- 5.79%
- Gross margin
- 72.03%
- Return on assets
- 10.03%
- Shares outstanding
- 1.77B
- Float
- 1.76B
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Analyst & Risk
- Beta (vs S&P 500)
- 0.28
- very stable
- 52-week change
- 37.67%
- Short % of float
- 1.38%
- Short ratio (days)
- 2.52
- Current ratio
- 0.8
- Quick ratio
- 0.52
- ROA
- 10.03%
- PEG ratio
- 0.42
- potentially undervalued
- EV / Revenue
- 8.17
- EV / EBITDA
- 17.16
- Revenue growth
- 12.40%
- Earnings growth
- -46.20%
- EBITDA
- 29.92B
- Free cash flow
- 20.81B
- Total cash
- 9.39B
- Total debt
- 72.91B
- Insider holdings
- 0.11%
- Institutional
- 76.86%
Recent rating changes
- 2026-07-15CitigroupNeutral → Neutralmain
- 2026-07-13UBSNeutral → Neutralmain
- 2026-07-13BMO CapitalOutperform → Outperformmain
- 2026-07-10B of A SecuritiesBuy → Buymain
- 2026-07-10RBC CapitalOutperform → Outperformmain
- 2026-07-10Wells FargoOverweight → Overweightmain
- 2026-07-09GuggenheimBuy → Buymain
- 2026-07-09JP MorganOverweight → Overweightmain
Financial documents
- Corporate Changes & Voting Matters8-K2026-07-06
- Annual report of employee stock purchase11-K2026-06-24
- Corporate Changes & Voting Matters8-K2026-06-22
- Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)SD2026-06-01
- Corporate Changes & Voting Matters8-K2026-05-12
- Periodic Financial Reports10-Q2026-05-08
- Corporate Changes & Voting Matters8-K2026-04-29
- Corporate Changes & Voting Matters8-K2026-04-03
- Proxy StatementsDEFA14A2026-03-23
- Proxy StatementsPRE 14A2026-03-09
- Corporate Changes & Voting Matters8-K2026-03-04
- Periodic Financial Reports10-K2026-02-20
Recent news
- How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend?Motley Fool8h ago
- What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment.Barrons.com3h ago
- My 2 Favorite Dividend Kings to Buy Right NowMotley Fool13h ago
- 3 Biggest Pharma Giants: Buy, Sell or Hold?24/7 Wall St.20h ago
- REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual MeetingPR Newswire1d ago
- IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors?Motley Fool1d ago
- AbbVie (ABBV) Wins EU Approval For Boey Frown Line Treatment In EuropeSimply Wall St.2d ago
- IXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy?Motley Fool1d ago
Related
Other assets in this category.
- 8306.TMitsubishi UFJ Financial Group, Inc.3,473 USD-4.30%
- 7203.TToyota Motor Corporation2,899.5 USD-0.33%
- 9984.TSoftBank Group Corp.5,424 USD-9.01%
- 6758.TSony Group Corporation3,470 USD+0.93%
- 6861.TKeyence Corporation70,880 USD-4.28%
- NVDANVIDIA Corporation202.81 USD-2.21%
- AAPLApple Inc.333.74 USD+0.14%
- 0700.HKTencent Holdings Limited477.8 USD+3.51%
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.